The treatment landscape of breast cancer has been revolutionized in the past 2 decades by the advent of more targeted options such as poly (ADP-ribose) polymerase inhibitors, PD1/PDL1 axis inhibitors, and antibody–drug conjugates. Here, CD274 is linked to breast carcinoma.